000 05046nam a22003855i 4500
001 281301
003 MX-SnUAN
005 20160429154059.0
007 cr nn 008mamaa
008 150903s2014 xxk| o |||| 0|eng d
020 _a9780857299109
_99780857299109
024 7 _a10.1007/9780857299109
_2doi
035 _avtls000334025
039 9 _a201509030804
_bVLOAD
_c201404300253
_dVLOAD
_y201402041138
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC254-282
100 1 _aLedermann, Jonathan A.
_eeditor.
_9306868
245 1 0 _aControversies in the Management of Gynecological Cancers /
_cedited by Jonathan A. Ledermann, Carien L. Creutzberg, Michael A. Quinn.
264 1 _aLondon :
_bSpringer London :
_bImprint: Springer,
_c2014.
300 _axv, 349 páginas 44 ilustraciones, 31 ilustraciones en color.
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
500 _aSpringer eBooks
505 0 _a1. Controversies in the Treatment of Women with Early Stage Epithelial Ovarian Cancer -- 2. Recurrent Ovarian Cancer: When to Treat and How to Assess -- 3. New Views of Ovarian Carcinoma Types: How will this Change Practice? -- 4. Lymphadenectomy in Endometrial Cancer: The Controversy Rages Unabated -- 5. What is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer? -- 6. Chemotherapy and/or Targeted Therapies for Advanced Endometrial Cancer: Time to Rethink? -- 7. Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries -- 8. What is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer? -- 9. Response as a Measure of Treatment Efficacy in Clinical Trials:  Should RECIST Be Abandoned? -- 10. What are the Treatment Options for Recurrent Ovarian Cancer? -- 11. How To Study Rare Gynaecological Tumours: Trials or Registries? -- 12. What is the Best Treatment Model for Gynaecological Cancers? Does Centralization Help? -- 13. When Should Surgery be Performed for the First-Line Treatment of Advanced Ovarian Cancer? -- 14. Does Intraperitoneal Therapy for Ovarian Cancer have a Future? -- 15. Maintenance Therapy for First-Line Treatment of Ovarian Cancer—Is this the Strategy for the Future? -- 16. What is the Value of Lymphadenectomy in Early Ovarian Cancer? -- 17. Sentinel Node Biopsy—Does it Help in the Management of Vulvar Cancer? -- 18. Controversies in the Management of Advanced Vulvar Cancer -- 19. Bowel Obstruction in Ovarian Cancer: To Operate or Not? -- 20. Early Cervical Cancer: Can Fertility be Safely Preserved? -- 21. What is the Role of PET/CT in Gynaecologic Cancers? -- 22. Do Intensity-Modulated Radiation, Image-Guided Radiation, and 3D Brachytherapy Significantly Advance Radiotherapeutic Management of Gynecologic Cancers? -- 23. What is the Place of Hormone Replacement Therapy in Ovarian, Endometrial, and Breast Cancer? -- 24. Familial Gynaecological Cancers: Whom to Screen and How to Manage? -- 25. Trial Design: Should Randomized Phase III Trials in Gynaecological Cancers be Abandoned? -- 26. How Should Early Gestational Trophoblastic Disease be Managed? -- 27. Should Every Woman with Gynaecologic Cancer Undergo Routine Screening for Psychological Distress and Sexual Dysfunction? -- 28. How Should Gynaecological Sarcomas be Managed? -- 29. What is the Future of Immunotherapy in Ovarian Cancer?.
520 _aGynecological cancers are some of the most commonly occurring malignancies in women. Despite their high incidence, treatment and management of these cancers remain controversial, with conflicting evidence about  many aspects of the disease.   Controversies in the Management of Gynecological Cancers offers a unique assessment of the opposing sides of the controversial issues associated with gynecological cancers, and aims to provide professionals in the field with a keener sense of the underlying evidence-base and a starting point from which to follow the ongoing debate. A section on the direction of future research to resolve these issues completes the discussion in each chapter.   This book will appeal to specialists, trainees and healthcare workers in gynecological oncology, gynecologists, medical oncologists and radiation oncologists, and is an excellent starting point for anyone who wishes to gain a better understanding of the complex nature of the management of gynecological malignancy.  
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aCreutzberg, Carien L.
_eeditor.
_9306869
700 1 _aQuinn, Michael A.
_eeditor.
_9306870
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9780857299093
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-0-85729-910-9
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c281301
_d281301